A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days.

Trial Profile

A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Registrational; Therapeutic Use
  • Sponsors Acerus Pharmaceuticals
  • Most Recent Events

    • 16 May 2017 Results assessing efficacy of intranasal testosterone gel administration outcomes on erectile function and mood correlations, presented at the 112th Annual Meeting of the American Urological Association.
    • 04 Apr 2017 Results from this and one more (phase I) study investigating the impact of seasonal allergies on absorption of Natesto nasal gel in hypogonadal men, presented at The 99th Annual Meeting of the Endocrine Society., presented at The 99th Annual Meeting of the Endocrine Society.
    • 04 Apr 2017 Results analysing one year hematologic safety of Natesto nasal gel in men with hypogonadism, presented at The 99th Annual Meeting of the Endocrine Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top